Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001213900-26-012759
Filing Date
2026-02-05
Accepted
2026-02-05 16:05:20
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 13757
2 JOINT FILING AGREEMENT ea027550001ex99-1_polaryx.htm EX-99.1 6417
  Complete submission text file 0001213900-26-012759.txt   21980
Mailing Address SOUTH TOWER, 140 E RIDGEWOOD AVENUE SUITE 415 PARAMUS NJ 07652
Business Address 140 EAST RIDGEWOOD AVENUE SUITE 415, SOUTH TOWER PARAMUS NJ 07652 201-940-7236
Polaryx Therapeutics, Inc. (Subject) CIK: 0002075320 (see all company filings)

EIN.: 000000000 | State of Incorp.: WY | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-95464 | Film No.: 26602866
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 7/F 80 GLOUCESTER ROAD WANCHAI Hong Kong 00000
Business Address 7/F 80 GLOUCESTER ROAD WANCHAI Hong Kong 00000 852 2155 9599
Mstone Partners Healthcare Ltd (Filed by) CIK: 0002104809 (see all company filings)

EIN.: 000000000 | State of Incorp.: K3 | Fiscal Year End: 1231
Type: SCHEDULE 13D